Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 --0%
EPS Growth %: -31.3%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
CCEL, FNGR, FAST, More
EPS Growth %: -31.3%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
- Mainframe shift weighs on Big Blue: IBM drops 14% on Q2 shortfall
- Beam Global reports Q2 2026 revenue above $8.5M, up 170% from Q1
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
